Paulo Thiago Souza-Santos

Dr. Paulo Thiago Souza-Santos

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
IGIsabela Gonzaga
Isabela Gonzaga
SLSheila Lima
Sheila Lima
PSPaulo Thiago Souza-Santos
Paulo Thiago Souza-Santos
TBTania Cristina Moita Blanco
Tania Cristina Moita Blanco
BRBruno Souza Bianchi de Reis
Bruno Souza Bianchi de Reis
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
Background: Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluatedEGFRmutation profile as well as the presence of mutations in hotspots ofKRASandBRAFin ESCC patients.Methods: We performed RT-qPCR, immunohistochemistry and Fluorescentin situhybridization to determine EGFR and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism analysis.Results: Our results showed an increasedEGFRmRNA expression in tumors compared to surrounding tissue (p T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC patients. The absence of mutations ofEGFR,KRASandBRAFas well as the overexpression of EGFR and HER2 in less than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with ESCC.Conclusion: HER receptors target therapies may have the potential to be effective in only a minor fraction of patients with ESCC.

16 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SLSheila Lima
Sheila Lima
HMHisham Mehanna
Hisham Mehanna
DCDiego Camuzi
Diego Camuzi
PSPaulo Thiago Souza-Santos
Paulo Thiago Souza-Santos
TSTatiana Simao
Tatiana Simao
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
Upper aerodigestive tract (UADT) tumors present different biological behavior and prognosis, suggesting specific molecular mechanisms underlying their development. However, they are rarely considered as single entities (particularly head and neck subsites) and share the most common genetic alterations. Therefore, there is a need for a better understanding of the global DNA methylation differences among UADT tumors. We performed a genome-wide DNA methylation analysis of esophageal (ESCC), laryngeal (LSCC), oral (OSCC) and oropharyngeal (OPSCC) squamous cell carcinomas, and their non-tumor counterparts. The unsupervised analysis showed that non-tumor tissues present markedly distinct DNA methylation profiles, while tumors are highly heterogeneous. Hypomethylation was more frequent in LSCC and OPSCC, while ESCC and OSCC presented mostly hypermethylation, with the latter showing a CpG island overrepresentation. Differentially methylated regions affected genes in 127 signaling pathways, with only 3.1% of these being common among different tumor subsites, but with different genes affected. The WNT signaling pathway, known to be dysregulated in different epithelial tumors, is a frequent hit for DNA methylation and gene expression alterations in ESCC and OPSCC, but mostly for genetic alterations in LSCC and OSCC. UADT tumor subsites present differences in genome-wide methylation regarding their profile, intensity, genomic regions and signaling pathways affected.

18 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
PNPedro Nicolau Neto
Pedro Nicolau Neto
PSPaulo Thiago Souza-Santos
Paulo Thiago Souza-Santos
MRMariana Ramundo
Mariana Ramundo
PVPriscila Valverde
Priscila Valverde
IMIvanir Martins
Ivanir Martins
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most incident tumors in the world, especially in developing countries, such as Brazil. Different from other tumors, LSCC prognosis did not improve during the past four decades. Therefore, the objective of this study was to develop biomarkers that can predict LSCC patient’s prognosis. Results: Transcriptome analysis pointed out 287 overexpressed genes in LSCC in comparison to adjacent mucosa. Among these, a gene-pattern signature was created with 24 genes associated with prognosis. The Bayesian clustering of both Brazil and The Cancer Genome Atlas (TCGA) data pointed out clusters of samples possessing significative differences in the prognosis, and the expression panel of three genes (ALCAM, GBP6, and ME1) was capable to distinguish patients with worse prognosis with an accuracy of 97%. Survival analyses with TCGA data highlighted ALCAM gene expression as an independent prognostic factor for LSCC. This was further confirmed through immunohistochemistry, using a validation set of Brazilian patients. ALCAM expression was not associated with prognosis for other head and neck tumor sites. Conclusion: ALCAM overexpression seems to be an independent prognosis biomarker for LSCC patients.

30 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CGCleandra Gregório
Cleandra Gregório
SLSheila Lima
Sheila Lima
BABárbara Alemar
Bárbara Alemar
MRMariana Recamonde-Mendoza
Mariana Recamonde-Mendoza
DCDiego Camuzi
Diego Camuzi
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality rates. PDAC initiation and progression are promoted by genetic and epigenetic dysregulation. Here, we aimed to characterize the PDAC DNA methylome in search of novel altered pathways associated with tumor development. We examined the genome-wide DNA methylation profile of PDAC in an exploratory cohort including the comparative analyses of tumoral and non-tumoral pancreatic tissues (PT). Pathway enrichment analysis was used to choose differentially methylated (DM) CpGs with potential biological relevance. Additional samples were used in a validation cohort. DNA methylation impact on gene expression and its association with overall survival (OS) was investigated from PDAC TCGA (The Cancer Genome Atlas) data. Pathway analysis revealed DM genes in the calcium signaling pathway that is linked to the key pathways in pancreatic carcinogenesis. DNA methylation was frequently correlated with expression, and a subgroup of calcium signaling genes was associated with OS, reinforcing its probable phenotypic effect. Cluster analysis of PT samples revealed that some of the methylation alterations observed in the Calcium signaling pathway seemed to occur early in the carcinogenesis process, a finding that may open new insights about PDAC tumor biology.

1 August 2016 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
EBEster de Andrade Barreto
Ester de Andrade Barreto
PSPaulo Thiago Souza-Santos
Paulo Thiago Souza-Santos
ABAnke Katharina Bergmann
Anke Katharina Bergmann
IOIvanir Martins de Oliveira
Ivanir Martins de Oliveira
LPLuciana Wernersbach Pinto
Luciana Wernersbach Pinto
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto

1 December 2018 in Translational Oncology
Verified
Journal Article
Open access
PSPaulo Thiago Souza-Santos
Paulo Thiago Souza-Santos
SLSheila Lima
Sheila Lima
PNPedro Nicolau Neto
Pedro Nicolau Neto
MBMariana Boroni
Mariana Boroni
NCNathalia Meireles Da Costa
Nathalia Meireles Da Costa
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
Esophageal squamous cell carcinoma (ESCC) is a frequent and lethal neoplasia. As recent advances in targeted therapy have not improved ESCC prognosis, characterization of molecular alterations associated to this tumor is of foremost relevance. In this study, we analyze, for the first time, the complete genomic profile of ESCC by RNA-seq. TP53 was the most frequently mutated gene in the investigation and validation sets (78.6% and 67.4%, respectively). Differential expression analysis between tumor and nontumor adjacent mucosa showed 6698 differentially expressed genes, most of which were overexpressed (74%). Enrichment analysis identified overrepresentation of Wnt pathway, with overexpressed activators and underexpressed inactivators, suggesting activation of canonical and noncanonical Wnt signaling pathways. Higher WNT7B expression was associated with poor prognosis. Twenty-one gene fusions were identified in 50% of tumors, none of which involving the same genes in different patients; 71% of fusions involved syntenic genes. Comparisons with TCGA data showed co-amplification of seven gene pairs involved in fusions in the present study (~33%), suggesting that these rearrangements might have been driven by chromoanagenesis. In conclusion, genomic alterations in ESCC are highly heterogeneous, impacting negatively in target therapy development.